JT takes up cobicistat for Japan but rejigs Toray nalfurafine tie-up
This article was originally published in Scrip
Japan Tobacco (JT) has acquired exclusive rights in Japan to Gilead Sciences' cobicistat, which it intends to develop and commercialise as a stand-alone booster agent for use with HIV drugs. The financial terms of the alliance were not disclosed.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.